📌 Key Takeaways
- On April 30, 2026, the FDA proposed removing semaglutide (Ozempic/Wegovy), tirzepatide (Mounjaro/Zepbound), and liraglutide from the 503B bulk compounding list.
The public comment deadline is June 29, 2026. - Compounded GLP-1s once accounted for ~30% of U.S. GLP-1 supply at peak.
A Novo Nordisk lawsuit found 86% impurity levels in some compounded semaglutide products,
and the FDA issued 50+ warning letters to compounding facilities in 2025. - The structural risk created by seeking cheaper drug sources —
counterfeit products, impurities, zero quality oversight —
is identical to Japan’s Mounjaro personal import and SNS resale problem.
NERO breaks down why.
On June 2, 2026, Osaka Prefectural Police referred three individuals for prosecution
over unauthorized Mounjaro (tirzepatide) sales via social media.
The Tokyo Metropolitan Government’s pharmaceutical division issued a direct public warning on official X (Twitter):
“Stop selling immediately.”
But this problem is not unique to Japan.
In the same week, a far-reaching regulatory shift was quietly advancing in the United States.
INDEX
What Is a “Compounded” GLP-1?
Compounding refers to the preparation of a drug — not from a commercially manufactured product,
but from bulk active pharmaceutical ingredients (APIs) — by a pharmacist or an outsourcing facility,
for individual patients or in large quantities.
In the U.S., two legal frameworks govern this:
503A (individual patient prescriptions at a pharmacy) and
503B (large-scale outsourcing facilities).
A “compounded GLP-1” is a version of drugs like Ozempic or Mounjaro
manufactured through this pathway —
separate from FDA-approved products, with different manufacturing standards.
Japan does not have an equivalent “compounding” framework.
However, GLP-1 drugs circulating through personal imports and SNS resale channels
carry functionally identical risks.
April 30, 2026: The FDA’s Decision
📅 Timeline: U.S. GLP-1 Compounding Regulation
Surging GLP-1 demand triggers nationwide shortages.
FDA adds semaglutide and tirzepatide to the drug shortage list —
legally permitting compounded manufacturing.
FDA declares shortage resolved for tirzepatide (Oct 2024) and semaglutide (Feb 2025).
The legal basis for compounding these drugs effectively collapses.
FDA issues 50+ warning letters to compounding facilities and telehealth operators.
Novo Nordisk files suit, citing 86% impurity levels in compounded semaglutide products.
FDA publishes a proposal to remove semaglutide, tirzepatide, and liraglutide
from the 503B bulk substances list (Federal Register 2026-08552).
FDA Commissioner Marty Makary states:
“When an FDA-approved drug is available, outsourcing facility compounding cannot legally proceed
without a clear clinical necessity.”
Public comment deadline: June 29, 2026.
“The same drug at one-third to one-fifth the price” —
the structural risks this situation creates are identical
whether we are talking about U.S. compounded GLP-1s
or Japan’s personal import and SNS resale market.
Risk 1: No Guarantee of Actual Active Ingredient
As Novo Nordisk’s litigation demonstrated,
compounded versions have been found to contain no active ingredient —
or entirely different substances.
The UK’s MHRA confirmed counterfeit Mounjaro pens containing insulin,
creating a serious risk of hypoglycemia from misidentified injection.
Risk 2: No Manufacturing or Storage Quality Assurance
The FDA explicitly states that compounded drugs
“are not manufactured under current Good Manufacturing Practice (cGMP) standards.”
Tirzepatide is a temperature-sensitive injectable.
Products resold via social media or marketplace apps
have unknown storage histories — degradation of the active compound is a real possibility.
Risk 3: No Access to Adverse Event Compensation (Japan)
In Japan, patients who obtain Mounjaro through personal import or SNS resale
are using it off-label for weight loss —
meaning they are ineligible for Japan’s national adverse drug reaction relief program
if a serious side effect occurs.
Any harm is entirely the patient’s own liability.
What Changes If This Rule Is Finalized?
If the FDA finalizes this proposal as a binding rule,
large-scale 503B outsourcing facility compounding of semaglutide, tirzepatide, and liraglutide
will be permanently prohibited.
503A pharmacy compounding (individual patient prescriptions) is not directly affected
and may continue in limited circumstances.
In the U.S., the price of brand-name GLP-1s — over $1,000/month — remains the central barrier to access.
The elimination of compounded alternatives will directly impact the business models of
telehealth platforms such as Hims, Ro, and LifeMD.
The implication for global consumers is clear:
The world’s most powerful drug regulator has determined
that sourcing GLP-1s through cheaper, unregulated channels is not acceptable.
The FDA’s regulatory action and Japan’s criminal referrals
look like separate events — but they share the same root.
The risks created by “the same drug at a lower price” —
impurities, counterfeits, zero medical oversight —
are a structural problem that crosses borders.
The clinical evidence for GLP-1s remains solid.
But where and how you obtain them
is what determines whether they work — and whether they’re safe.
That is what NERO exists to communicate.
“Cheap” is the price tag on risk.
The gap between compounded and brand-name pricing
was always the cost of quality assurance,
safety monitoring, and manufacturing standards.
Summary
- On April 30, 2026, the FDA proposed removing semaglutide, tirzepatide, and liraglutide
from the 503B bulk compounding list (Federal Register 2026-08552).
Public comment deadline: June 29, 2026. - Compounded GLP-1s once held ~30% of U.S. supply.
Novo Nordisk litigation found 86% impurity levels in some products;
the FDA issued 50+ warning letters in 2025. - The risks of sourcing GLP-1s through cheaper, unregulated channels —
impurities, counterfeits, absent quality control —
are structurally identical in both the U.S. compounding market
and Japan’s Mounjaro SNS resale and personal import market. - In Japan, patients using Mounjaro obtained through personal import or resale
are ineligible for the national adverse drug reaction relief program.
Any harm is entirely the patient’s own responsibility.
However, unapproved GLP-1 drugs imported from overseas
are circulating through personal import services and SNS resale channels.
These products carry the same quality and purity risks
identified in U.S. compounded GLP-1 investigations.
so there is no direct legal impact on Japan.
However, restricting U.S. compounding supply channels
may redirect non-regulated products through alternative international routes,
potentially increasing availability of unverified GLP-1 products in other markets.
The core message for Japanese consumers remains unchanged:
regardless of origin, GLP-1 drugs obtained through unofficial channels
carry no quality guarantee.
The UK’s MHRA confirmed that counterfeit Mounjaro KwikPens
featured packaging and printing of extremely high quality —
indistinguishable from authentic products even by trained professionals.
The only reliable way to ensure product authenticity
is to obtain it through a licensed medical provider with a valid prescription.
Sources
FDA, “List of Bulk Drug Substances for Which There Is a Clinical Need Under Section 503B of the Federal Food, Drug, and Cosmetic Act,” Federal Register 2026-08552, April 30, 2026 /
FDA Press Release, “FDA Proposes to Exclude Semaglutide, Tirzepatide, and Liraglutide on 503B Bulks List,” April 30, 2026 /
Orrick, “FDA Moves to Shut the Door on Large-Scale Compounding of GLP-1 Drugs,” May 1, 2026 /
Pharmacy Times, “FDA Moves to Permanently Close the Door on Compounded GLP-1s,” June 2026 /
Medical News Today, “FDA proposes ban on bulk compounding of semaglutide, tirzepatide, liraglutide,” 2026 /
onhealthcare.tech, “FDA Closes the 503B Bulks Door on Semaglutide, Tirzepatide, and Liraglutide — Part II,” May 3, 2026 /
UK MHRA, “Falsified Mounjaro (tirzepatide) KwikPen alert,” February 2026 /
IAPAM, “May 2026 Aesthetic Medicine Update,” June 3, 2026
